Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Ralph Alvarez, a director at Eli Lilly, acquired 19 shares of common stock through a deferral plan on January 16, 2024.

Summary

• Ralph Alvarez, a director of Eli Lilly & Co, acquired 19 shares of common stock on January 16, 2024.
• The shares were acquired at a price of $634.57 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez beneficially owns 53,891 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine transaction related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among publicly listed companies, including pharmaceutical companies like Pfizer (PFE) and Merck (MRK).
• These plans are often used to align the interests of directors with those of shareholders.
• The specific terms of deferral plans can vary, but the general concept of deferring compensation into company stock is widely used.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, Stock Units, Common Stock, Ralph Alvarez, LLY